ArticleThe western journal of emergency medicine2011
Reversal of warfarin-induced hemorrhage in the emergency department.
Article in The western journal of emergency medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Association Between Risk Scores for Genetic Variants and Percentage of Time in Therapeutic Range for Participants With Atrial Fibrillation, Deep Vein Thrombosis, and/or Intracardiac Thrombosis Taking Warfarin
Investigation of Genetic Variations on Patients With Adverse Drug Events While on Direct Oral Anticoagulants (DOACs)
Investigation of Genetic Variations on Patients With Adverse Events While on Direct Oral Anticoagulants (DOACs)
Correlation Between Bleeding Complication and Treatment Failure of DOAC and Its Predictions Based on Cipherome's Pharmacogenomic Technology
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Prothrombin complex concentrate in major bleeding associated with DOACs; an updated systematic review and meta-analysis.Journal of thrombosis and thrombolysis · 2021Pooled it
- AI-assisted warfarin dose optimisation with CURATE.AI for clinical impact: Retrospective data analysis.Bioengineering & translational medicine · 2025Article
- Evolving Strategies for Use of Phytochemicals in Prevention and Long-Term Management of Cardiovascular Diseases (CVD).International journal of molecular sciences · 2024Review
- Treatment of Ruptured Wide-Necked Aneurysms using a Microcatheter Injectable Biomaterial.Advanced materials (Deerfield Beach, Fla.) · 2023Article
- Bacterial-Nanocellulose-Based Biointerfaces and Biomimetic Constructs for Blood-Contacting Medical Applications.ACS materials Au · 2023Review
- Article
- Anticoagulation and Antiplatelet Agents in Peripheral Arterial Interventions.Seminars in interventional radiology · 2022Review
- Fixed-Dose Factor Eight Inhibitor Bypassing Activity (FEIBA) in the Management of Warfarin-Associated Coagulopathies.Pharmacy (Basel, Switzerland) · 2022Article
- Nanocomposite Hydrogel with Tantalum Microparticles for Rapid Endovascular Hemostasis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Article
- Emergency Reversal of Anticoagulation.The western journal of emergency medicine · 2019Review
- The Advantages and Challenges of Diversity in Pharmacogenomics: Can Minority Populations Bring Us Closer to Implementation?Clinical pharmacology and therapeutics · 2019Review
- Thromboembolic Risk of 4-Factor Prothrombin Complex Concentrate versus Fresh Frozen Plasma for Urgent Warfarin Reversal in the Emergency Department.The western journal of emergency medicine · 2019Article
- Cardiovascular Pharmacogenomics: Does It Matter If You're Black or White?Annual review of pharmacology and toxicology · 2019Review
- Multiple spontaneous hemorrhages after commencing warfarin therapy.SAGE open medical case reports · 2018Article
- Spontaneous subcutaneous tissue haematoma associated with warfarin.BMJ case reports · 2016Article
- Direct-Acting Oral Anticoagulants: Practical Considerations for Emergency Medicine Physicians.Emergency medicine international · 2016Review
- Interference of M-protein on prothrombin time test - case report.Biochemia medica · 2016Article
- A Bayesian decision support tool for efficient dose individualization of warfarin in adults and children.BMC medical informatics and decision making · 2015Article
- Reversal of oral anticoagulation.Pharmacotherapy · 2013Review
- Anticoagulant-induced subdural hemorrhage in a patient with Guillain-Barré syndrome: An anesthetic challenge.Journal of anaesthesiology, clinical pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Warfarin, an oral vitamin K antagonist, is used to prevent arterial and venous thromboembolism in patients suffering from a multitude of diseases. In 2004, 31 million warfarin prescriptions were dispensed in the United States. Warfarin inhibits the activation of the vitamin K-dependent clotting factors (Factors II, VII, IX, and X) and regulatory proteins (proteins C, S, and Z). It is one of the leading drugs implicated in emergency room visits for adverse drug reactions. Annually the frequency of bleeding complications associated with overanticoagulation is 15% to 20%, with fatal bleeds measuring as high as 1% to 3%. The most effective method of warfarin reversal involves the use of Four Factor Prothrombin Complex Concentrate (PCC), which is widely used throughout Europe but is unavailable in the United States. The current therapies available to emergency room physicians in the United States are fresh frozen plasma, recombinant Factor VIIa (rFVIIa), Factor Eight Inhibitory Bypassing Activity, or Three Factor PCC concomitantly administered with vitamin K. We review the advantages and disadvantages of these therapies and recommend Three Factor PCC with small doses of rFVIIa and with vitamin K in life-threatening situations if Four Factor PCC is unavailable.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.